Invivyd reports preliminary Q3 2024 PEMGARDA revenue of $9.3M, withdraws 2024 guidance, targets 1H 2025 profitability

Invivyd, Inc.

2024-Q3 EPS reported -$1.28 revenue$11,564,000

Preliminary Q3 2024 PEMGARDA net product revenue of $9.3M; cash and equivalents ~$107M as of Sept 30.
Withdraws prior 2024 revenue guidance of $150-200M citing late-Q3 FDA Fact Sheet warning on pemivibart activity.
Targets near-term profitability in 1H 2025 using existing cash, anticipated revenue growth, and operational efficiencies.
Phase 3 CANOPY data: PEMGARDA provided 64% RRR vs placebo in months 7-12, total 12-month RRR 76% (nominal p<0.0001).
Expects to end 2024 with $65M+ cash; no new safety signals in months 7-12 follow-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.